AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16424720 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirecumbent position
Number of subjects: 221
Study 16424720 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 221
Study 12601237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine repair of myelomeningocele
Number of subjects: 77
Study 12601237 — intervention group
Group type: COMPARATOR
Intervention: Traditional postgestational repair of myelomeningocele
Number of subjects: 77
Study 11291606 — intervention group
Group type: COMPARATOR
Intervention: Venous blood gasometry (vbg) after exercise of antebrachial muscles in diabetic patients
Number of subjects: 32
Study 11291606 — intervention group
Group type: COMPARATOR
Intervention: Laser Doppler fluxometry (LDF) in diabetic patients
Number of subjects: 32
Study 8664529 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibition
Number of subjects: 0
Study 8664529 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 8664529 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amiodarone
Number of subjects: 0
Study 8664529 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphic nonsustained ventricular tachycardia
Number of subjects: 0
Study 8664529 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia in dilated cardiomyopathy and hypertrophic cardiomyopathy
Number of subjects: 0
Study 1518670 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically prepared group given atropine as premedication
Number of subjects: 0
Study 1518670 — intervention group
Group type: COMPARATOR
Intervention: Control group given narcotic-sedative premedication
Number of subjects: 0
Study 6097117 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmenoxime (0.5 to 2.0 g every six hours)
Number of subjects: 59
Study 6097117 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (0.5 to 2.0 g every six hours)
Number of subjects: 59
Study 30927417 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg/day
Number of subjects: 173
Study 30927417 — intervention group
Group type: COMPARATOR
Intervention: Ganirelix 0.25 mg/day
Number of subjects: 173
Study 30927417 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 173
Study 30927417 — intervention group
Group type: COMPARATOR
Intervention: Ganirelix
Number of subjects: 173
Study 28687937 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nutraceutical (red yeast rice 10 mg, phytosterols 800 mg, L-tyrosol 5 mg)
Number of subjects: 60
Study 25448925 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral fundoplication (TF)
Number of subjects: 129
Study 25448925 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery with omeprazole (control)
Number of subjects: 129
Study 25448925 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TF and control)
Number of subjects: 129
Study 23643425 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic electrical somatosensory stimulation (TENS) at 2 Hz
Number of subjects: 31
Study 23643425 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional exercise training (EXTR)
Number of subjects: 31
Study 23643425 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CTRL)
Number of subjects: 31
Study 21682909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo WiiActive programme
Number of subjects: 80
Study 21682909 — intervention group
Group type: COMPARATOR
Intervention: Standard gym-based rehabilitation
Number of subjects: 80
Study 19555395 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40-80 mg/day)
Number of subjects: 16
Study 19555395 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol (5-10 mg/day)
Number of subjects: 16
Study 19555395 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 16
Study 16623990 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of a central line
Number of subjects: 132
Study 16623990 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of a urinary catheter
Number of subjects: 132
Study 16623990 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical site infection
Number of subjects: 132
Study 16623990 — intervention group
Group type: EXPERIMENTAL
Intervention: Population attributable fraction for urinary catheter
Number of subjects: 132
Study 16623990 — intervention group
Group type: EXPERIMENTAL
Intervention: Population attributable fraction for central line
Number of subjects: 132
Study 16623990 — intervention group
Group type: EXPERIMENTAL
Intervention: Population attributable fraction for surgical site infection
Number of subjects: 132
Study 15572496 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system
Number of subjects: 59
Study 15572496 — intervention group
Group type: COMPARATOR
Intervention: Transcervical resection of the endometrium
Number of subjects: 59
Study 11371728 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2-DG) infusion
Number of subjects: 39
Study 9773262 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/GSD
Number of subjects: 46
Study 9773262 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/NGM
Number of subjects: 46
Study 8005128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril treatment for 12 weeks
Number of subjects: 54
Study 8005128 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 54
Study 2585534 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ppm formaldehyde
Number of subjects: 24
Study 2585534 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/m3 respirable activated carbon aerosol
Number of subjects: 24
Study 2585534 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ppm formaldehyde plus activated carbon aerosol
Number of subjects: 24
Study 2585534 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 24
Study 1094748 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically-applied buphenin (in a gel basis)
Number of subjects: 0
Study 1094748 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31911249 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 31911249 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 0
Study 31911249 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 0
Study 31911249 — intervention group
Group type: COMPARATOR
Intervention: Vildagliptin
Number of subjects: 0
Study 29846131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined video-based training and conditioning (COM)
Number of subjects: 20
Study 29846131 — intervention group
Group type: EXPERIMENTAL
Intervention: Separated conditioning and video-based training (SEP)
Number of subjects: 20
Study 29846131 — intervention group
Group type: COMPARATOR
Intervention: Conditioning only (CON)
Number of subjects: 20
Study 28171710 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1199
Study 28171710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study 26444689 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacus-based mental calculation (AMC) training, 2-hour sessions every week since primary school entry.
Number of subjects: 70
Study 26444689 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacus-based mental calculation (AMC) training
Number of subjects: 70
Study 26444689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AMC training)
Number of subjects: 70
Study 22762460 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa microtablets (LC-5)
Number of subjects: 11
Study 22762460 — intervention group
Group type: COMPARATOR
Intervention: levodopa/carbidopa/entacapone (LCE)
Number of subjects: 11
Study 21700646 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient withdrawal programme
Number of subjects: 82
Study 21700646 — intervention group
Group type: COMPARATOR
Intervention: In-patient withdrawal programme
Number of subjects: 82
Study 18816001 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT)
Number of subjects: 48
Study 18816001 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 48
Study 15888605 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta oscillations during episodic trace access
Number of subjects: 0
Study 15888605 — intervention group
Group type: EXPERIMENTAL
Intervention: LORETA source localization
Number of subjects: 0
Study 15888605 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic encoding stages
Number of subjects: 0
Study 15888605 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow wave activity
Number of subjects: 0
Study 12372443 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (3.75 mg i.m. every 28 days for 3 months)
Number of subjects: 51
Study 12372443 — intervention group
Group type: COMPARATOR
Intervention: Standard controlled ovarian hyperstimulation
Number of subjects: 51
Study 10674010 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 30 mg daily for 1 year
Number of subjects: 634
Study 10674010 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide 600, methotrexate 40, 5‐fluorouracil 600 mg/m2 i.v. every 4 weeks, 9 cycles) + TAM
Number of subjects: 634
Study 10674010 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 600, methotrexate 40, 5‐fluorouracil 600 mg/m2 i.v. every 4 weeks, 9 cycles)
Number of subjects: 634
Study 10674010 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF + TAM
Number of subjects: 634
Study 10674010 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 634
Study 7586959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) monitoring
Number of subjects: 16
Study 7586959 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 16
Study 2038944 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cannulated cancellous bone screws
Number of subjects: 33
Study 2038944 — intervention group
Group type: COMPARATOR
Intervention: Screw-angle plate device
Number of subjects: 33
Study 6108783 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 6108783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 6108783 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 6432201 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive episiotomy policy (episiotomy restricted to fetal indications)
Number of subjects: 1000
Study 6432201 — intervention group
Group type: COMPARATOR
Intervention: Liberal episiotomy policy (episiotomy used more liberally to prevent perineal tears)
Number of subjects: 1000
Study 6432201 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive episiotomy policy
Number of subjects: 1000
Study 6432201 — intervention group
Group type: COMPARATOR
Intervention: Liberal episiotomy policy
Number of subjects: 1000
Study 31937160 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal progesterone 200 mg daily until 36+6 weeks or spontaneous delivery
Number of subjects: 160
Study 31937160 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered in a similar manner
Number of subjects: 160
Study 31680085 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment combined with benzbromarone
Number of subjects: 66
Study 31680085 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 66
Study 30672211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pestle needling therapy, applied once daily for 4 weeks.
Number of subjects: 132
Study 30672211 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment and nursing for diabetes (Control group).
Number of subjects: 132
Study 26909824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal ECT
Number of subjects: 65
Study 26909824 — intervention group
Group type: COMPARATOR
Intervention: Right Unilateral ECT
Number of subjects: 65
Study 24164872 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiCell tampon
Number of subjects: 31
Study 24164872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid impregnated tampon
Number of subjects: 31
Study 24164872 — intervention group
Group type: EXPERIMENTAL
Intervention: ChitoHem tampon
Number of subjects: 31
Study 22679715 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 64
Study 22679715 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Bacillus licheniformis and Deanxit)
Number of subjects: 64
Study 20638648 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninformative onset cue
Number of subjects: 0
Study 20638648 — intervention group
Group type: EXPERIMENTAL
Intervention: Color cue
Number of subjects: 0
Study 18046717 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 weeks of peginterferon-alpha2b (1.5 mug/kg/week) and ribavirin (800-1400 mg/day)
Number of subjects: 0
Study 18046717 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks of peginterferon-alpha2b (1.5 mug/kg/week) and ribavirin (800-1400 mg/day)
Number of subjects: 0
Study 18046717 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 weeks of peginterferon-alpha2b and ribavirin
Number of subjects: 0
Study 18046717 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks of peginterferon-alpha2b and ribavirin
Number of subjects: 0
Study 16036011 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telecare using a videophone for the management of acute exacerbations of COPD (intervention period: 2 weeks)
Number of subjects: 22
Study 11952268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal conflict behaviors expressed in videotaped simulations of interadult disputes
Number of subjects: 0
Study 11952268 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressions of fear
Number of subjects: 0
Study 10890258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (3-g single dose)
Number of subjects: 749
Study 10890258 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin (100-mg capsules for 7 days)
Number of subjects: 749
Study 10890258 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 749
Study 7724749 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐DOPA alone (n = 16)
Number of subjects: 22
Study 7724749 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐11‐L‐DOPA and C‐11‐5‐HTP (n = 6)
Number of subjects: 22
Study 7724749 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 22
Study 2075773 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative short-term antibiotic prophylaxis
Number of subjects: 162
Study 2075773 — intervention group
Group type: COMPARATOR
Intervention: Postoperative antibiotic treatment
Number of subjects: 162
Study 2075773 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 162
Study 6942648 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy diet
Number of subjects: 69
Study 6942648 — intervention group
Group type: COMPARATOR
Intervention: Casein diet
Number of subjects: 69
Study 30787601 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg SBB‐PE
Number of subjects: 12
Study 30787601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29958855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir for 12 weeks (n=101)
Number of subjects: 204
Study 29958855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir plus Ribavirin for 12 weeks (n=103)
Number of subjects: 204
Study 26997182 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing tobacco use trajectory
Number of subjects: 684
Study 26997182 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple substance use trajectory
Number of subjects: 684
Study 26997182 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription drug misuse trajectory
Number of subjects: 684
Study 26997182 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use trajectory
Number of subjects: 684
Study 25217039 — intervention group
Group type: EXPERIMENTAL
Intervention: SaltSwitch smartphone app
Number of subjects: 300
Study 25217039 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 300
Study 22381604 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate medical treatment (oral mifepristone followed by vaginal misoprostol, n = 91)
Number of subjects: 182
Study 22381604 — intervention group
Group type: COMPARATOR
Intervention: Sequential management (1 week of watchful waiting followed by medical treatment if necessary, n = 91)
Number of subjects: 182
Study 22381604 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate medical treatment
Number of subjects: 182
Study 22381604 — intervention group
Group type: COMPARATOR
Intervention: Sequential management
Number of subjects: 182
Study 20628332 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise (trunk muscle strengthening and stretching exercises)
Number of subjects: 201
Study 20628332 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (control group)
Number of subjects: 201
Study 17711944 — intervention group
Group type: EXPERIMENTAL
Intervention: TQS (Tétanos Quick Stick) test
Number of subjects: 611
Study 17711944 — intervention group
Group type: COMPARATOR
Intervention: Standard vaccination history assessment without TQS
Number of subjects: 611
Study 15607213 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed 25-foot walk (T25FW)
Number of subjects: 32
Study 15607213 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced auditory serial addition test (PASAT)
Number of subjects: 32
Study 15607213 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-hole peg test (9HP)
Number of subjects: 32
Study 12112798 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol plus BDP 200 microg bid by metered dose inhaler (MDI) with a spacer
Number of subjects: 31
Study 12112798 — intervention group
Group type: COMPARATOR
Intervention: salbutamol MDI plus a placebo
Number of subjects: 31
Study 10354329 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention on clinical reasoning
Number of subjects: 0
Study 10354329 — intervention group
Group type: COMPARATOR
Intervention: Control group (no teaching intervention)
Number of subjects: 0
Study 7497688 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed arthroplasty group
Number of subjects: 30
Study 7497688 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 1798317 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg.kg‐1) taken immediately prior to exercise
Number of subjects: 6
Study 1798317 — intervention group
Group type: COMPARATOR
Intervention: Control or placebo conditions
Number of subjects: 6
Study 7019706 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supervised exercise program
Number of subjects: 258
Study 7019706 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 258
Study 29120277 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 1107
Study 26886503 — intervention group
Group type: EXPERIMENTAL
Intervention: DEVS program (intervention group)
Number of subjects: 1752
Study 26886503 — intervention group
Group type: COMPARATOR
Intervention: Usual drug education program (control group)
Number of subjects: 1752
Study 25046272 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous MNX (0.9 mg/kg)
Number of subjects: 50
Study 25046272 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study 22777113 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS)
Number of subjects: 34
Study 22777113 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline + 6% dextran 70 (HSD)
Number of subjects: 34
Study 22777113 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 34
Study 21063148 — intervention group
Group type: EXPERIMENTAL
Intervention: Two above one below approach with intermediate screws at the fracture site
Number of subjects: 27
Study 21063148 — intervention group
Group type: COMPARATOR
Intervention: Long segment posterior spinal fusion
Number of subjects: 27
Study 17927497 — intervention group
Group type: COMPARATOR
Intervention: Fish oil, 2 g tid plus placebo capsules bid (n = 12)
Number of subjects: 34
Study 17927497 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil, 2 g tid plus celecoxib 200 mg bid (n = 10)
Number of subjects: 34
Study 15837438 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific electronically generated hypertension decision support system (DSS)
Number of subjects: 588
Study 15837438 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 588
Study 11856592 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with bone marrow or stem cell support
Number of subjects: 0
Study 11856592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0
Study 11856592 — intervention group
Group type: COMPARATOR
Intervention: Single agent chemotherapy (doxorubicin, epirubicin, ifosfamide)
Number of subjects: 0
Study 9655795 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler scanning during cold stress
Number of subjects: 0
Study 9655795 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler scanning during heat stress
Number of subjects: 0
Study 9655795 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler scanning during LBNP
Number of subjects: 0
Study 8180354 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 0
Study 8180354 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticytokine treatment
Number of subjects: 0
Study 8180354 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiprotease treatment
Number of subjects: 0
Study 8180354 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of cervical, decidual, and/or chorionic extracellular matrix proteins
Number of subjects: 0
Study 2574304 — intervention group
Group type: EXPERIMENTAL
Intervention: AIK-C vaccine at 4-5 months
Number of subjects: 5
Study 2574304 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb vaccine at 4-5 months
Number of subjects: 5
Study 2574304 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Schwarz vaccine at 4-5 months
Number of subjects: 5